Comprehensive Stock Comparison
Compare CytomX Therapeutics, Inc. (CTMX) vs Regeneron Pharmaceuticals, Inc. (REGN) vs Centessa Pharmaceuticals plc (CNTA) vs Immunome, Inc. (IMNM) vs Celldex Therapeutics, Inc. (CLDX) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Growth | CTMX | 36.4% revenue growth vs CNTA's -100.0% |
| Value | CTMX | Better valuation composite |
| Quality / Margins | REGN | 31.4% net margin vs CLDX's -172.5% |
| Stability / Safety | REGN | Beta 0.58 vs IMNM's 1.42 |
| Dividends | REGN | 0.4% yield; 1-year raise streak; CTMX, CNTA, IMNM, CLDX pay no meaningful dividend |
| Momentum (1Y) | CTMX | +6.9% vs REGN's +12.4% |
| Efficiency (ROA) | CTMX | 17.7% ROA vs IMNM's -74.4% |
Who Each Stock Is For
Income & stability
Growth exposure
Long-term compounding (10Y)
Sleep-well-at-night portfolio
Defensive / Recession hedge
Business Model
What each company does and how it makes money
CytomX Therapeutics is an oncology-focused biopharmaceutical company that develops conditionally activated antibody therapeutics using its proprietary Probody technology platform. It generates revenue primarily through strategic collaborations and licensing deals with major pharmaceutical partners — including AbbVie, Amgen, and Bristol-Myers Squibb — which provide upfront payments, milestone payments, and potential future royalties on any commercialized products. The company's key competitive advantage is its Probody platform technology, which creates conditionally activated therapeutics that remain inactive until they reach the tumor microenvironment, potentially improving safety and efficacy compared to traditional antibody therapies.
Regeneron Pharmaceuticals is a biotechnology company that discovers, develops, and commercializes innovative medicines for serious diseases. It generates revenue primarily from sales of its flagship products — EYLEA for eye diseases (~60% of revenue) and Dupixent for inflammatory conditions (~30%) — with additional income from collaborations and royalties. The company's competitive advantage lies in its proprietary VelocImmune technology platform for creating human antibodies and its deep expertise in genetic research, which enables rapid drug discovery and development.
Centessa Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel medicines for serious diseases. It generates revenue primarily through research collaborations and licensing agreements — though as a pre-commercial company, it currently relies on equity financing and partnerships to fund development. The company's competitive advantage lies in its asset-centric model — each program operates as an independent "company" with dedicated resources and accountability — and its LockBody platform technology designed to create targeted cancer therapies with reduced systemic toxicity.
Immunome is a biopharmaceutical company that discovers and develops antibody therapeutics for cancer and infectious diseases. It generates revenue primarily through research collaborations and licensing agreements — with no commercial products yet — as it advances its pipeline of antibody candidates. The company's key advantage lies in its proprietary discovery platform that identifies human antibodies from patient immune responses, potentially yielding more effective and safer therapeutic candidates.
Celldex Therapeutics is a clinical-stage biopharmaceutical company developing targeted antibody therapies for cancer and inflammatory diseases. It generates revenue primarily through research collaborations and licensing agreements — with future income dependent on successful clinical development and commercialization of its pipeline candidates. The company's competitive advantage lies in its proprietary antibody platform technology and focused expertise in developing monoclonal and bispecific antibodies against validated targets.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Segment breakdown not available.
Financial Metrics Comparison
Side-by-side fundamentals across 5 stocks. BestLagging
Financial Scorecard
REGN leads in 2 of 6 categories (Financial Metrics, Profitability & Efficiency). CTMX leads in 1 (Valuation Metrics). 2 tied.
Financial Metrics (TTM)
REGN is the larger business by revenue, generating $14.3B annually — 9561.9x CLDX's $2M. REGN is the more profitable business, keeping 31.4% of every revenue dollar as net income compared to CLDX's -172.5%. On growth, REGN holds the edge at +2.5% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | CTMXCytomX Therapeuti… | REGNRegeneron Pharmac… | CNTACentessa Pharmace… | IMNMImmunome, Inc. | CLDXCelldex Therapeut… |
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $114M | $14.3B | $15M | $10M | $2M |
| EBITDAEarnings before interest/tax | $25M | $4.2B | -$213M | -$232M | -$284M |
| Net IncomeAfter-tax profit | $28M | $4.5B | -$243M | -$223M | -$259M |
| Free Cash FlowCash after capex | -$72M | $3.2B | -$181M | -$192M | -$213M |
| Gross MarginGross profit ÷ Revenue | +100.0% | +86.3% | +100.0% | -4.2% | +100.0% |
| Operating MarginEBIT ÷ Revenue | +20.5% | +25.7% | -14.3% | -24.2% | -191.6% |
| Net MarginNet income ÷ Revenue | +24.7% | +31.4% | -16.2% | -23.0% | -172.5% |
| FCF MarginFCF ÷ Revenue | -63.7% | +22.0% | -12.1% | -19.8% | -142.2% |
| Rev. Growth (YoY)Latest quarter vs prior year | -82.2% | +2.5% | — | -100.0% | -93.6% |
| EPS Growth (YoY)Latest quarter vs prior year | -2.3% | -2.5% | -10.8% | +16.7% | -73.2% |
Valuation Metrics
At 14.1x trailing earnings, CTMX trades at a 25% valuation discount to REGN's 18.8x P/E. On an enterprise value basis, CTMX's 15.0x EV/EBITDA is more attractive than REGN's 21.6x.
| Metric | CTMXCytomX Therapeuti… | REGNRegeneron Pharmac… | CNTACentessa Pharmace… | IMNMImmunome, Inc. | CLDXCelldex Therapeut… |
|---|---|---|---|---|---|
| Market CapShares × price | $430M | $107.6B | $3.6B | $2.0B | $2.0B |
| Enterprise ValueMkt cap + debt − cash | $401M | $91.4B | $3.3B | $1.9B | $2.0B |
| Trailing P/EPrice ÷ TTM EPS | 14.13x | 18.84x | -13.04x | -4.37x | -7.72x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 17.25x | — | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | 2.98x | — | — | — |
| EV / EBITDAEnterprise value multiple | 15.00x | 21.64x | — | — | — |
| Price / SalesMarket cap ÷ Revenue | 3.11x | 7.50x | — | 221.74x | 1334.98x |
| Price / BookPrice ÷ Book value/share | — | 2.72x | 7.66x | 7.08x | 3.80x |
| Price / FCFMarket cap ÷ FCF | — | 26.36x | — | — | — |
Profitability & Efficiency
CTMX delivers a 26.1% return on equity — every $100 of shareholder capital generates $26 in annual profit, vs $-84 for IMNM. CLDX carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to CNTA's 0.29x. On the Piotroski fundamental quality scale (0–9), REGN scores 7/9 vs IMNM's 1/9, reflecting strong financial health.
| Metric | CTMXCytomX Therapeuti… | REGNRegeneron Pharmac… | CNTACentessa Pharmace… | IMNMImmunome, Inc. | CLDXCelldex Therapeut… |
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | +26.1% | +14.4% | -80.5% | -84.4% | -49.1% |
| ROA (TTM)Return on assets | +17.7% | +11.1% | -54.1% | -74.4% | -44.4% |
| ROICReturn on invested capital | — | +12.4% | -91.8% | -7.0% | -35.2% |
| ROCEReturn on capital employed | +62.0% | +10.8% | -47.9% | -195.6% | -44.7% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 7 | 3 | 1 | 3 |
| Debt / EquityFinancial leverage | — | 0.09x | 0.29x | 0.03x | 0.00x |
| Net DebtTotal debt minus cash | -$29M | -$16.2B | -$266M | -$139M | -$27M |
| Cash & Equiv.Liquid assets | $38M | $18.9B | $383M | $143M | $29M |
| Total DebtShort + long-term debt | $9M | $2.7B | $117M | $5M | $2M |
| Interest CoverageEBIT ÷ Interest expense | — | 120.42x | -20.50x | — | — |
Total Returns (with DRIP)
A $10,000 investment in REGN five years ago would be worth $16,977 today (with dividends reinvested), compared to $5,472 for IMNM. Over the past 12 months, CTMX leads with a +693.0% total return vs REGN's +12.4%. The 3-year compound annual growth rate (CAGR) favors CNTA at 96.9% vs CLDX's -11.1% — a key indicator of consistent wealth creation.
| Metric | CTMXCytomX Therapeuti… | REGNRegeneron Pharmac… | CNTACentessa Pharmace… | IMNMImmunome, Inc. | CLDXCelldex Therapeut… |
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | +26.4% | +0.8% | +13.4% | +5.0% | +11.4% |
| 1-Year ReturnPast 12 months | +693.0% | +12.4% | +72.7% | +132.6% | +46.3% |
| 3-Year ReturnCumulative with dividends | +149.8% | +3.4% | +663.1% | +378.3% | -29.7% |
| 5-Year ReturnCumulative with dividends | -36.4% | +69.8% | +23.5% | -45.3% | +6.7% |
| 10-Year ReturnCumulative with dividends | -58.4% | +104.7% | +23.5% | +62.5% | -70.5% |
| CAGR (3Y)Annualised 3-year return | +35.7% | +1.1% | +96.9% | +68.5% | -11.1% |
Risk & Volatility
REGN is the less volatile stock with a 0.58 beta — it tends to amplify market swings less than IMNM's 1.42 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CLDX currently trades 96.2% from its 52-week high vs IMNM's 79.1% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | CTMXCytomX Therapeuti… | REGNRegeneron Pharmac… | CNTACentessa Pharmace… | IMNMImmunome, Inc. | CLDXCelldex Therapeut… |
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.08x | 0.58x | 0.98x | 1.42x | 1.14x |
| 52-Week HighHighest price in past year | $6.35 | $821.11 | $30.58 | $27.65 | $31.29 |
| 52-Week LowLowest price in past year | $0.40 | $476.49 | $9.60 | $5.15 | $14.40 |
| % of 52W HighCurrent price vs 52-week peak | +84.6% | +95.2% | +87.8% | +79.1% | +96.2% |
| RSI (14)Momentum oscillator 0–100 | 52.0 | 49.1 | 65.7 | 42.9 | 71.7 |
| Avg Volume (50D)Average daily shares traded | 2.6M | 687K | 1.2M | 1.5M | 547K |
Analyst Outlook
Analyst consensus: CTMX as "Buy", REGN as "Buy", CNTA as "Buy", IMNM as "Buy", CLDX as "Buy". Consensus price targets imply 86.2% upside for CTMX (target: $10) vs -20.2% for CLDX (target: $24). REGN is the only dividend payer here at 0.44% yield — a key consideration for income-focused portfolios.
| Metric | CTMXCytomX Therapeuti… | REGNRegeneron Pharmac… | CNTACentessa Pharmace… | IMNMImmunome, Inc. | CLDXCelldex Therapeut… |
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $10.00 | $857.17 | $37.33 | $35.29 | $24.00 |
| # AnalystsCovering analysts | 21 | 48 | 11 | 9 | 19 |
| Dividend YieldAnnual dividend ÷ price | — | +0.4% | — | — | — |
| Dividend StreakConsecutive years of raises | 1 | 1 | — | — | — |
| Dividend / ShareAnnual DPS | — | $3.41 | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +3.2% | 0.0% | 0.0% | 0.0% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Jun 21 | Feb 26 | Change |
|---|---|---|---|
| CytomX Therapeutics… (CTMX) | 100 | 88.84 | -11.2% |
| Regeneron Pharmaceu… (REGN) | 100 | 150.03 | +50.0% |
| Centessa Pharmaceut… (CNTA) | 108.41 | 115.82 | +6.8% |
| Immunome, Inc. (IMNM) | 100 | 127.02 | +27.0% |
| Celldex Therapeutic… (CLDX) | 100 | 88.77 | -11.2% |
Regeneron Pharmaceu… (REGN) returned +70% over 5 years vs Immunome, Inc. (IMNM)'s -45%. A $10,000 investment in REGN 5 years ago would be worth $16,977 today (including dividends reinvested).
Chart 2Revenue Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| CytomX Therapeutics… (CTMX) | $15M | $138M | +818.1% |
| Regeneron Pharmaceu… (REGN) | $4.9B | $14.3B | +195.1% |
| Centessa Pharmaceut… (CNTA) | $0.00 | $0.00 | — |
| Immunome, Inc. (IMNM) | $0.00 | $9M | — |
| Celldex Therapeutic… (CLDX) | $7M | $2M | -77.9% |
Regeneron Pharmaceuticals, Inc.'s revenue grew from $4.9B (2016) to $14.3B (2025) — a 12.8% CAGR.
Chart 3Net Margin Trend — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| CytomX Therapeutics… (CTMX) | -3.9% | 23.1% | +689.4% |
| Regeneron Pharmaceu… (REGN) | 18.4% | 31.4% | +70.5% |
| Centessa Pharmaceut… (CNTA) | -22.0% | -22.0% | +0.0% |
| Immunome, Inc. (IMNM) | -7.6% | -32.4% | -325.3% |
| Celldex Therapeutic… (CLDX) | -18.9% | -172.5% | -810.9% |
Regeneron Pharmaceuticals, Inc.'s net margin went from 18% (2016) to 31% (2025).
Chart 4P/E Ratio History — 9 Years
| Stock | 2017 | 2025 | Change |
|---|---|---|---|
| Regeneron Pharmaceu… (REGN) | 36.4 | 18.6 | -48.9% |
Regeneron Pharmaceuticals, Inc. has traded in a 9x–36x P/E range over 9 years; current trailing P/E is ~19x.
Chart 5EPS Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| CytomX Therapeutics… (CTMX) | -1.63 | 0.38 | +123.3% |
| Regeneron Pharmaceu… (REGN) | 7.7 | 41.48 | +438.7% |
| Centessa Pharmaceut… (CNTA) | -0.08 | -2.06 | -2551.2% |
| Immunome, Inc. (IMNM) | -7.18 | -5 | +30.4% |
| Celldex Therapeutic… (CLDX) | -18.99 | -3.9 | +79.5% |
Regeneron Pharmaceuticals, Inc.'s EPS grew from $7.70 (2016) to $41.48 (2025) — a 21% CAGR.
Chart 6Free Cash Flow — 5 Years
CytomX Therapeutics, Inc. generated $-87M FCF in 2024 (+28% vs 2021). Regeneron Pharmaceuticals, Inc. generated $4B FCF in 2025 (-38% vs 2021).
CTMX vs REGN vs CNTA vs IMNM vs CLDX: Key Questions Answered
9 questions · data-driven answers · updated daily
01Is CTMX or REGN or CNTA or IMNM or CLDX a better buy right now?
CytomX Therapeutics, Inc. (CTMX) offers the better valuation at 14.1x trailing P/E, making it the more compelling value choice. Analysts rate CytomX Therapeutics, Inc. (CTMX) a "Buy" — based on 21 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — CTMX or REGN or CNTA or IMNM or CLDX?
On trailing P/E, CytomX Therapeutics, Inc. (CTMX) is the cheapest at 14.1x versus Regeneron Pharmaceuticals, Inc. at 18.8x.
03Which is the better long-term investment — CTMX or REGN or CNTA or IMNM or CLDX?
Over the past 5 years, Regeneron Pharmaceuticals, Inc. (REGN) delivered a total return of +69.8%, compared to -45.3% for Immunome, Inc. (IMNM). A $10,000 investment in REGN five years ago would be worth approximately $17K today (assuming dividends reinvested). Over 10 years, the gap is even starker: REGN returned +104.7% versus CLDX's -70.5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — CTMX or REGN or CNTA or IMNM or CLDX?
By beta (market sensitivity over 5 years), Regeneron Pharmaceuticals, Inc. (REGN) is the lower-risk stock at 0.58β versus Immunome, Inc.'s 1.42β — meaning IMNM is approximately 146% more volatile than REGN relative to the S&P 500. On balance sheet safety, Celldex Therapeutics, Inc. (CLDX) carries a lower debt/equity ratio of 0% versus 29% for Centessa Pharmaceuticals plc — giving it more financial flexibility in a downturn.
05Which has better profit margins — CTMX or REGN or CNTA or IMNM or CLDX?
Regeneron Pharmaceuticals, Inc. (REGN) is the more profitable company, earning 31.4% net margin versus -172.5% for Celldex Therapeutics, Inc. — meaning it keeps 31.4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: REGN leads at 25.7% versus -191.6% for CLDX. At the gross margin level — before operating expenses — CTMX leads at 100.0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is CTMX or REGN or CNTA or IMNM or CLDX more undervalued right now?
Analyst consensus price targets imply the most upside for CTMX: 86.2% to $10.00.
07Which pays a better dividend — CTMX or REGN or CNTA or IMNM or CLDX?
In this comparison, REGN (0.4% yield) pays a dividend. CTMX, CNTA, IMNM, CLDX do not pay a meaningful dividend and should not be held primarily for income.
08Is CTMX or REGN or CNTA or IMNM or CLDX better for a retirement portfolio?
For long-horizon retirement investors, Regeneron Pharmaceuticals, Inc. (REGN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.58), +104.7% 10Y return). Both have compounded well over 10 years (REGN: +104.7%, IMNM: +62.5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between CTMX and REGN and CNTA and IMNM and CLDX?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. In terms of investment character: CTMX is a small-cap deep-value stock; REGN is a mid-cap quality compounder stock; CNTA is a small-cap quality compounder stock; IMNM is a small-cap quality compounder stock; CLDX is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.